MUC1 dendritic cell vaccine, that introduces cellular immune response against MUC1, was tested in Phase I/II clinical trial in the treatment of various advanced malignancies, including ovarian cancer [93]. This evidence concerns the gene MUC1 and ovarian carcinoma.